The epitranscriptome

Registration Fees (include access to all of the talks, digital poster sessions and online group discussions, and help us cover our costs to run the event. For further information please refer to the FAQ page):

Accredited journalists may be eligible to register for a complimentary registration. Registrants may be required to provide accreditation or equivalent proof of press membership after registration. Please contact Aline Schnieder for more information.

Confirmation and Payment

Registration will be on a first-come first-served basis. Your place can only be confirmed after payment of the registration fee.
Types of payments accepted are international bank transfers and credit card payments.

Abstract submission

Abstract submission deadline: 10 January 2022 (23:59 Europe/Berlin)

Only registered participants are eligible to submit an abstract. We only accept online abstract submissions.

After you have logged in and successfully registered, you will receive an email asking you to submit your abstract.  Click on the link provided and enter your abstract in the text box provided. Alternatively you can submit your abstract by clicking on the link on the confirmation page directly after registering.

When submitting your abstract you can also apply for an oral or poster presentation. A selection process will take place with the results announced 2-3 weeks after the abstract submission deadline.

Financial Fee Waivers

All academic and student registrants are invited to apply for a registration fee waiver, provided by the EMBL Advanced Training Centre Corporate Partnership Programme and EMBO. The registration fee waiver covers the registration sum that you have paid to attend the meeting. Conference participants are not required to pre-pay the registration fee to be selected for a fee waiver for a virtual meeting. If you have already paid the registration fee and are awarded a fee waiver, it will be reimbursed after the meeting.

Childcare Grants

For participants and speakers with childcare responsibilities there is the possibility to apply for a grant, provided by the EMBL Advanced Training Centre Corporate Partnership Programme and EMBO, to offset childcare costs incurred when participating at a virtual event. Eligible costs include fees for a babysitter or childcare facility or travel costs for a care giver. Please note that priority will be given to early stage researchers. Costs will be reimbursed after the meeting only once a reimbursement form and original receipts have been received. Attendance at the event is required in order to be eligible to receive the reimbursement. In order to apply for this grant, you must be registered by the abstract submission deadline.

Application

Applications for financial assistance can be submitted via the submission portal* (for the submission of abstracts for conferences) by completing the Financial Assistance Application Section (underneath the section for entering abstract/motivation letter information). The link to the portal can be found in the registration confirmation email that you will receive after registering for the conference.

For conferences, if you are not submitting an abstract, you can still apply for financial assistance in the submission portal. Take a look at the instructions for applying for financial assistance. Note that priority will be given to those submitting an abstract to present at the conference. In your application you will be asked to answer questions regarding your motivation for applying, and, for registration fee waivers, the reasons why your lab cannot fund your attendance and how your attendance will make a difference to your career. Application for financial support will not affect the outcome of your registration application.

Selection

The scientific organisers will select the recipients of registration fee waivers during the abstract selection process for conferences and the participant selection process for courses. Results will be announced approximately 3 – 4 weeks before the event start date. Selection results do not impact your admission to the meeting. Registration fee waiver selection is based on your current work or study location, your motivation for applying, the reasons for needing financial support and the impact this event will have on your career. Childcare grants are allocated based on career stage, with priority given to early stage researchers.

Further details

Check our list of external funding opportunities and read our information on attending a conference as an event reporter.

For further information about financial assistance please refer to the FAQ page.

Guidelines

Please do:

• Use the event-specific hashtag as communicated during the event for any related tweets
• Tweet unless the speaker specifically says otherwise
• Be mindful of unpublished data
• Be respectful in tone and content

Please don’t:

• Share Slack, live stream or poster session links with others
• Broadcast the conference to unregistered participants
• Capture, transmit or redistribute data presented at the meeting unless presenter gives explicit consent
• Use offensive language in your posts
• Engage in rudeness or personal attacks

Additional information can be found in our Code of Conduct.

Health and well-being

It is important to stay healthy and move around, especially when you are attending an event virtually. We have put together a few coffee break stretches and yoga videos. You can find these under ‘resources’ on the conference platform.

How to ask questions

Please use the Q&A function. It is possible to send a direct message to participants, poster presenters, and speakers within the conference platform.

If you have any other questions, you can go to the Help Desk on the conference platform. Click on ‘more’ on the top menu and click Help Desk. 

Time zone

The programme is planned based on Central European Time (CET) or Central European Summer Time (CEST) unless otherwise stated. As many virtual participants are attending from around the world, we do our best to accommodate as many time zones as possible when creating the programme. Please take your time zone into consideration when planning your attendance. Remember to set your time zone in your account. 

Virtual event platforms

We are using a virtual event platform for this conference. More information about the platform will be shared ahead of the conference.

Please find additional information including FAQs and terms and conditions on our Information for Participants page.

Speaker: Prof. Joel Yisraeli
Chairman, Department of Developmental Biology and Cancer Research,
Institute for Medical Research – Israel-Canada
Faculty of Medicine, Hebrew University of Jerusalem, Israel

Igf2bp1 is an oncofetal RNA binding protein whose expression in numerous types of cancers is associated with upregulation of key pro-oncogenic RNAs, poor prognosis, and reduced survival. Importantly, Igf2bp1 synergizes with mutations in Kras to enhance signaling and oncogenic activity, suggesting that molecules inhibiting Igf2bp1 could have therapeutic potential. We have performed a high-throughput fluorescence polarization (FP) screen for small molecule inhibitors of IGF2BP1 RNA binding and isolated a small molecule that interacts with Igf2bp1 KH3 and KH4 domains and inhibits binding to Kras RNA. In cells, the compound reduces the level of Kras and other Igf2bp1 mRNA targets, lowers Kras protein, and inhibits downstream signaling, wound healing and growth in soft agar, all in the absence of any toxicity. After a second, optimization, screen, we have performed a multi-omic analysis to identify changes, following inhibitor treatment of H1299 lung carcinoma cells, in direct RNA binding sites (eCLIP), RNA expression (RNAseq), and protein expression (mass spectrometry). This analysis has revealed several cancer progression pathways that are inhibited and has identified novel mechanisms through which IGF2BP1 influences cancer. The inhibitor is currently being tested in vivo and shows promising results in shrinking primary tumors and preventing metastases in mice.  This work presents an avenue for improving the prognosis of Igf2bp1-expressing tumors in lung and other cancers.